Search

Displaying results 81 - 90 of 5935 in total
  1. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion

  2. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

  3. Drug

    Nicotine

    go.drugbank.com/drugs/DB00184
    ApprovedInvestigational

    Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of it...

    Products: Care One Nicotine
  4. Drug

    Dimenhydrinate

    go.drugbank.com/drugs/DB00985
    ApprovedInvestigational

    effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.

    Synonyms: (O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate, O-benzhydryldimethylaminoethanol 8-chlorotheophyllinateProducts: REISETABLETT DIMEN 50MG/WL, VOMEX A KINDER SUP 70MG FO
  5. Drug

    Vitamin E

    go.drugbank.com/drugs/DB00163
    ApprovedInvestigationalNutraceuticalVet approved

    In 1922, vitamin E was demonstrated to be an essential nutrient[A32448]. … Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].

    Mixtures: One A Day Multiple Vit W Minerals, Vege Swiss One Multivitamin W Chel Mins Tab
  6. Drug

    Lutein

    go.drugbank.com/drugs/DB00137
    ApprovedNutraceutical

    Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very

    Mixtures: Strovite One Caplets
  7. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    one to three prior therapies. … Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received

  8. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    ApprovedInvestigational

    [L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease

  9. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    Corifollitropin alfa, also known as _Elonva_ is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries. … This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].

  10. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. … [L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen